Language
We detect your regional language is French. Do you want to change site's language to French? You may choose other languages.International
English
中文
русск
français
español
العربية
User Center
My Training Class
Feedback
GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies | Vol.9, Issue.7/8 | | Pages 17-8
KS virus controversy.
Dr. Yuan Chang and her research group believe they have fulfilled the epidemiological criteria for establishing the KSHV (herpes virus) as the cause of Kaposi's Sarcoma (KS), but Dr. Gallo and others still question the virus's role. If KS is caused by KSHV, there is a possibility that an antiviral drug may have a therapeutic effect. Foscarnet, in one open-label study of five people with KS, proved to be effective in three of the cases by causing a remission and even clearing external (and in one case internal) lesions for more than a year after just one or two brief courses. Another retrospective analysis of 20,228 showed people with HIV/AIDS treated with foscarnet were 70 percent less likely to develop KS. Such research evidence warrants further study; one open-label trial for 25 people is recruiting. Call Clare Kenny or Lorrie Jondreau at (212) 263-5244 for more information.
Original Text (This is the original text for your reference.)
KS virus controversy.
Dr. Yuan Chang and her research group believe they have fulfilled the epidemiological criteria for establishing the KSHV (herpes virus) as the cause of Kaposi's Sarcoma (KS), but Dr. Gallo and others still question the virus's role. If KS is caused by KSHV, there is a possibility that an antiviral drug may have a therapeutic effect. Foscarnet, in one open-label study of five people with KS, proved to be effective in three of the cases by causing a remission and even clearing external (and in one case internal) lesions for more than a year after just one or two brief courses. Another retrospective analysis of 20,228 showed people with HIV/AIDS treated with foscarnet were 70 percent less likely to develop KS. Such research evidence warrants further study; one open-label trial for 25 people is recruiting. Call Clare Kenny or Lorrie Jondreau at (212) 263-5244 for more information.
+More
Translate engine
Article's language
Action
Report
Share
Recommended articles
Report
Select your report category*
Reason*
Your level privilege is in sufficient. You can go to the “User Center” to view your level information and perform points tasks to upgrade your level.
New sign-in location：
Last sign-in location：
Last sign-in date：
About to jump to an external site.
Security unknown, whether to continue